|
Volumn 44, Issue 1, 2012, Pages 182-184
|
Effectiveness of rituximab and intravenous immunoglobulin therapy in renal transplant recipients with chronic active antibody-mediated rejection
|
Author keywords
[No Author keywords available]
|
Indexed keywords
HLA ANTIBODY;
IMMUNOGLOBULIN;
MEPREDNISONE;
PREDNISOLONE;
PROTEIN;
RITUXIMAB;
CHRONIC ACTIVE ANTIBODY MEDIATED REJECTION;
CLINICAL ARTICLE;
CONFERENCE PAPER;
DELAYED GRAFT FUNCTION;
DISEASE SEVERITY;
DRUG EFFICACY;
GENERAL CONDITION DETERIORATION;
GLOMERULOPATHY;
GRAFT REJECTION;
HUMAN;
KIDNEY TRANSPLANTATION;
OUTCOME ASSESSMENT;
PRIORITY JOURNAL;
PROTEINURIA;
SINGLE DRUG DOSE;
TREATMENT RESPONSE;
ADULT;
ANTIBODIES, MONOCLONAL, MURINE-DERIVED;
BIOPSY;
CHRONIC DISEASE;
DRUG THERAPY, COMBINATION;
FEMALE;
GRAFT REJECTION;
HLA ANTIGENS;
HUMANS;
IMMUNITY, HUMORAL;
IMMUNOGLOBULINS, INTRAVENOUS;
IMMUNOSUPPRESSIVE AGENTS;
ISOANTIBODIES;
KIDNEY TRANSPLANTATION;
MALE;
PROTEINURIA;
REPUBLIC OF KOREA;
TIME FACTORS;
TREATMENT OUTCOME;
|
EID: 84863355667
PISSN: 00411345
EISSN: 18732623
Source Type: Journal
DOI: 10.1016/j.transproceed.2011.12.006 Document Type: Conference Paper |
Times cited : (27)
|
References (6)
|